Name: MicroRNA Amplification and Recognition through Locked-nucleic-acid In situ Hybridization as a Novel Detection and Quantification Method (Video) | JoVE Journal
Uploaded: 2025-10-07T12:30:00.000+00:00
Duration: 9 min 6 s
Description: Learn a tandem immunofluorescence hybridization assay to detect and quantify microRNAs and proteins in FFPE tissue. This method preserves tissue integrity while enabling spatial analysis of tumor microenvironments.

ai_agent_IP

ai_agent

maintenance

instantTrialDurationMinutes

isBiopharma

enableNewMyJoveSectionDesign

educationFeatures

seoMetaApi

ai_copilot_institution_blacklist

ai_chat_institution_blacklist

freeAccessWindow

ssoRoleCapture

scheduledMaintenanceBanner

joveLabsFeatures

disable_autoplay_for_bots

extended_trial_duration

5 minutes

We would like to acknowledge the following people, Chi Lam Au Yeung and Manjunath Nimmakayalu, who were a part of Basant&#39;s thesis committee while the assay was in development. Also, Samuel Mok, who sectioned and provided the samples used. Lastly, we acknowledge Johan Dor&#233; and Dan Winkowski, who provided extensive assistance during analysis and the use of the Visiopharm software. This research was funded in part by the Ovarian Cancer Research Alliance (OCRA 811621 and 891490), the Sie Foundation, and the Stephanie C. Stelter Endowment Fund. This research was performed in collaboration with the Flow Cytometry and Cellular Imaging Core Facility, which is supported in part by the National Institutes of Health through M. D. Anderson&#39;s Cancer Center Support Grant P30 CA016672 and Jared Burks&#39; NCI&#39;s Research Specialist 1 R50 CA243707-01A1. Dr. Au Yeungs&#39;s ORCA Fund 89165 supported the purchase of reagents for mircoRNA amplifications.

This protocol uses formalin-fixed paraffin-embedded (FFPE) tissues of human ovarian tumor tissue sections from patients with HGSC. These samples were collected from previously untreated patients undergoing primary cytoreductive surgery for ovarian cancer. All samples and clinical data were obtained from the ovarian cancer repository of the Department of Gynecologic Oncology and Reproductive Medicine under protocols approved by the University of Texas MD Anderson&#39;s Institutional Review Board. Written informed consent from the patients was obtained by front desk personnel, and the studies were conducted in accordance with recognized ethical guidelines.
1. Tissue preparation
<ol>
	<li>Bake all FFPE samples overnight at 60 &#176;C and clean each piece of equipment and tools with RNAse-free water. Ensure the sections are around 5 &#181;m thick. 
	NOTE: This protocol has been optimized for ovarian tumors but can potentially be used with other tissue types after further testing.</li>
	<li>Perform deparaffinization with three rounds of Xylene for 5 min each round, and 10 rounds of rehydration for 3 min each round (100% ethanol (EtOH) 2x, 95% EtOH 2x, 70% EtOH 2x, 50% EtOH 2x, 30% EtOH 2x). Wash with 1x tris-buffered saline (TBS) for 2 min, once. 
	NOTE: This dewaxing step, although recommended, is optional and dependent on tissue type.</li>
	<li>After deparaffinization and rehydration, apply a solution of 3% Hydrogen Peroxide (H2O2) for 10 min. Wash for 2 min with 1x TBS, 2x. Then, apply a solution of 3.7% Paraformaldehyde (PFA) for 10 min. Wash for 2 min with 1x TBS, 2x. 
	NOTE: This step is optional and should only be considered for fatty tissues, or samples that are prone to detachment.</li>
	<li>Proceed to the first round of antigen retrieval. This protocol uses the EZ-Retriever IR System. Following the system&#39;s instructions, microwave the samples while submerged in fresh EZ-AR1 buffer at 95 &#176;C for 15 min. Leave to cool for 20 min.</li>
	<li>Wash for 2 min with 1x TBS. Then for 2 min with 1x TBS-T (1x TBS with 0.1% Tween), 2x.</li>
</ol>
2. Protein application
<ol>
	<li>Draw a barrier around each tissue section with a hydrophobic barrier pen.</li>
	<li>Add 1x Antibody blocking solution (enough to cover the entire tissue area) and incubate for 30 min at room temperature in a humidity chamber (ambient and uncontrolled humidity).</li>
	<li>Subsequently, dilute the first primary antibody with the same blocking solution, apply enough to cover the entire tissue area, and leave to incubate for 1 h at room temperature in a humidity chamber. 
	NOTE: During the development of this protocol, Anti-CD8 was used at a dilution of 1:75.</li>
	<li>Wash for 2 min in 1x TBS-T, 3x. Then, add the Anti-Ms + Rb HRP and leave the samples to incubate for 10 min at room temperature in a humidity chamber (ambient and uncontrolled humidity).</li>
	<li>Wash for 2 min in 1x TBS-T, 3x. Dilute the first fluorophore with the amplification dilutant at 1:100 and incubate for 10 min at room temperature in the humidity chamber. 
	NOTE: During the development of this protocol, a 690 nm emission fluorophore was used. From this point, it is recommended to use minimal lighting for the rest of the procedure after applying the first round of fluorophore.</li>
	<li>Wash for 2 min in 1x TBS-T, 3x. Begin the second round of antibody staining with the second round of antigen retrieval in the microwave, by again submerging the samples in fresh EZ-AR1 buffer at 95 &#176;C for 15 min, then cooling for 20 min.</li>
	<li>Wash for 2 min with 1x TBS. Then wash for 2 min with 1x TBS-T, 2x.</li>
	<li>Apply the 1x Antibody blocking solution again for 30 min in a humidity chamber at room temperature (ambient and uncontrolled humidity).</li>
	<li>Dilute the second primary antibody with the same blocking solution, apply enough to cover the entire tissue area, and leave to incubate overnight at 4 &#176;C in a humidity chamber for at least 16 h. 
	NOTE: During the development of this protocol, Anti-EpCAM was used at a dilution of 1:200.</li>
	<li>Begin the following day by washing for 2 min in 1x TBS-T, 3x. Then add the Anti-Ms + Rb HRP and leave the samples to incubate for 10 min at room temperature in a humidity chamber (ambient and uncontrolled humidity).</li>
	<li>Wash for 2 min in 1x TBS-T, 3x. Dilute the second fluorophore with the amplification dilutant at 1:100 and incubate for 10 min at room temperature in the humidity chamber. 
	NOTE: During the development of this protocol, a 620 nm emission fluorophore was used.</li>
</ol>
3. Probe application
<ol>
	<li>Wash for 2 min in 1x TBS-T, 3x.</li>
	<li>Start the third and final antigen retrieval with EZ-AR1 Elegance in the microwave at 107 &#176;C for 15 min. Leave to cool for 20 min. Wash for 3 min in 1x TBS.</li>
	<li>Apply RNAscope Protease Plus (enough to cover the entire tissue area) and keep at 40 &#176;C for 30 min. Use an oven. Wash for 5 min in 1x TBS, 2x.</li>
	<li>Perform probe preparation by denaturation at 90 &#176;C for 4 min of the miRNA LNA probe. Then immediately dilute the probe using miRNA-ISH buffer. Vortex and spin the probe solution. 
	NOTE: During the development of this protocol miR-181c-3p target probe was used at a dilution of 1:250.</li>
	<li>Apply probe (enough to cover the entire tissue area) and place back in the oven for 1 h at 60 &#176;C. Wash for 5 min in 5x Saline Sodium Citrate (SSC) buffer.</li>
	<li>Perform five stringent washes in SSC prewarmed at 60 &#176;C in the following order and dilutions for 5 min each round: one round of 5x SSC, two rounds of 1x SSC, and two rounds of 0.2x SSC.</li>
	<li>Wash for 5 min in 0.2x SSC at room temperature. Incubate with blocking buffer for 30 min at room temperature in a humidified chamber. Use a combination of 1x TBS and 0.5% Blocking Reagent Powder, make sure to vortex and spin the blocking solution before application.</li>
	<li>Apply an Anti-Digoxigenin (Mouse) HRP Conjugate (for these samples, a dilution of 1:500 was used) and incubate for 30 min at room temperature in a humidified chamber.</li>
	<li>Wash for 5 min in 1x TBS-T, 3x Apply a recommended dilution of 1:50 of the Tyramide Signal Amplification Plus Cyanine 3 (TSA+Cy3) fluorophore for 10 min in a humidity chamber at room temperature (ambient and uncontrolled humidity). Make sure to vortex and spin the TSA+Cy3 solution before application.</li>
	<li>Wash for 5 min in 1x TBS-T, 3x.</li>
</ol>
4. Nuclear staining and mounting
<ol>
	<li>Apply 4&#39;,6-diamidino-2-phenylindole (DAPI) working solution (enough to cover the entire tissue area) for 5 min at room temperature in a humidified chamber (ambient and uncontrolled humidity). 
	NOTE: For this protocol, a dilution of 1:1000 was used, with the working DAPI stock diluted in TBS.)</li>
	<li>Wash for 5 min in 1x TBS-T, 3x. At completion, apply coverslips using mounting media and leave slides to dry for 10 min. Store slides at 4 &#176;C in the dark between 24-72 h before imaging and up to three months after.</li>
</ol>
5. Imaging and analysis
<ol>
	<li>For imaging, use a slide scanning microscope (preferred) at 40x magnification.</li>
	<li>Perform subsequent quantitative analysis to enumerate puncta utilizing DAPI and protein counterstaining for cell segmentation and phenotyping. 
	NOTE: During this protocol, we utilized imaging with a Phenoimager HT. Full slides scans were captured at a 40x magnification utilizing appropriate filters for the fluorophores present, and multiplexed images were then exported as OME-TIFF files. The scanned images were then uploaded into Visiopharm Image Analysis Software for quantitative analysis.</li>
</ol>

<ol><li>Smolarz, B., Nowak, A. Z., Romanowicz, H. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Breast+cancer-epidemiology%2C+classification%2C+pathogenesis+and+treatment+%28review+of+literature%29%5BTitle%5D)+AND+%22Cancers%22%5BJournal%5D)">Breast cancer-epidemiology, classification, pathogenesis and treatment (review of literature).</a> Cancers. 14 (10), 2569(2022).</li>
<li>Davis-Dusenbery, B. N., Hata, A. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Microrna+in+cancer%3A+The+involvement+of+aberrant+microrna+biogenesis+regulatory+pathways%5BTitle%5D)+AND+%22Genes+Cancer%22%5BJournal%5D)">Microrna in cancer: The involvement of aberrant microrna biogenesis regulatory pathways.</a> Genes Cancer. 1 (11), 1100-1114 (2010).</li>
<li>Peng, Y., Croce, C. M. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((The+role+of+microRNAs+in+human+cancer%5BTitle%5D)+AND+%22Signal+Transduct+Targeted+Ther%22%5BJournal%5D)">The role of microRNAs in human cancer.</a> Signal Transduct Targeted Ther. 1 (1), 15004(2016).</li>
<li>Shi, Y., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Mirnas+and+cancer%3A+Key+link+in+diagnosis+and+therapy%5BTitle%5D)+AND+%22Genes%22%5BJournal%5D)">Mirnas and cancer: Key link in diagnosis and therapy.</a> Genes. 12 (8), 1289(2021).</li>
<li>Juźwik, C. A., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((MicroRNA+dysregulation+in+neurodegenerative+diseases%3A+A+systematic+review%5BTitle%5D)+AND+%22Prog+Neurobiol%22%5BJournal%5D)">MicroRNA dysregulation in neurodegenerative diseases: A systematic review.</a> Prog Neurobiol. 182, 101664(2019).</li>
<li>Pauley, K. M., Cha, S., Chan, E. K. L. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Microrna+in+autoimmunity+and+autoimmune+diseases%5BTitle%5D)+AND+%22J+Autoimmun%22%5BJournal%5D)">Microrna in autoimmunity and autoimmune diseases.</a> J Autoimmun. 32 (3-4), 189-194 (2009).</li>
<li>Lee, Y. S., Dutta, A. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Micrornas+in+cancer%5BTitle%5D)+AND+%22Ann+Rev+Pathol+Mech+Dis%22%5BJournal%5D)">Micrornas in cancer.</a> Ann Rev Pathol Mech Dis. 4 (1), 199-227 (2009).</li>
<li>Thomson, D. W., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Assessing+the+gene+regulatory+properties+of+argonaute-bound+small+rnas+of+diverse+genomic+origin%5BTitle%5D)+AND+%22Nuc+Acids+Res%22%5BJournal%5D)">Assessing the gene regulatory properties of argonaute-bound small rnas of diverse genomic origin.</a> Nuc Acids Res. 43 (1), 470-481 (2015).</li>
<li>Kim, Y. K., Han, J. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Nobel-winning+microRNA%2C+the+microRNAestro+of+gene+silencing%5BTitle%5D)+AND+%22Mol+Cells%22%5BJournal%5D)">Nobel-winning microRNA, the microRNAestro of gene silencing.</a> Mol Cells. 47 (11), 100123(2024).</li>
<li>Lai, X., Eberhardt, M., Schmitz, U., Vera, J. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Systems+biology-based+investigation+of+cooperating+microRNAs+as+monotherapy+or+adjuvant+therapy+in+cancer%5BTitle%5D)+AND+%22Nuc+Acid+Res%22%5BJournal%5D)">Systems biology-based investigation of cooperating microRNAs as monotherapy or adjuvant therapy in cancer.</a> Nuc Acid Res. 47 (15), 7753-7766 (2019).</li>
<li>Garzon, R., Marcucci, G., Croce, C. M. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Targeting+micrornas+in+cancer%3A+Rationale%2C+strategies+and+challenges%5BTitle%5D)+AND+%22Nat+Rev+Drug+Disc%22%5BJournal%5D)">Targeting micrornas in cancer: Rationale, strategies and challenges.</a> Nat Rev Drug Disc. 9 (10), 775-789 (2010).</li>
<li>Jiao, X., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((MicroRNA%3A+The+impact+on+cancer+stemness+and+therapeutic+resistance%5BTitle%5D)+AND+%22Cells%22%5BJournal%5D)">MicroRNA: The impact on cancer stemness and therapeutic resistance.</a> Cells. 9 (1), 8(2019).</li>
<li>Lin, B., Jiang, J., Jia, J., Zhou, X. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Recent+advances+in+exosomal+miRNA+biosensing+for+liquid+biopsy%5BTitle%5D)+AND+%22Molecules%22%5BJournal%5D)">Recent advances in exosomal miRNA biosensing for liquid biopsy.</a> Molecules. 27 (21), 7145(2022).</li>
<li>Farrell, D., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((The+identification+of+circulating+miRNAs+in+bovine+serum+and+their+potential+as+novel+biomarkers+of+early+Mycobacterium+avium+subsp.+paratuberculosis+infection%5BTitle%5D)+AND+%22PLoS+One%22%5BJournal%5D)">The identification of circulating miRNAs in bovine serum and their potential as novel biomarkers of early Mycobacterium avium subsp. paratuberculosis infection.</a> PLoS One. 10 (7), e0134310(2015).</li>
<li>Aparicio-Puerta, E., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Srnabench+and+srnatoolbox+2022+update%3A+Accurate+mirna+and+sncrna+profiling+for+model+and+non-model+organisms%5BTitle%5D)+AND+%22Nuc+Acid+Res%22%5BJournal%5D)">Srnabench and srnatoolbox 2022 update: Accurate mirna and sncrna profiling for model and non-model organisms.</a> Nuc Acid Res. 50 (W1), W710-W717 (2022).</li>
<li>Friedländer, M. R., Mackowiak, S. D., Li, N., Chen, W., Rajewsky, N. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Mirdeep2+accurately+identifies+known+and+hundreds+of+novel+microRNA+genes+in+seven+animal+clades%5BTitle%5D)+AND+%22Nuc+Acid+Res%22%5BJournal%5D)">Mirdeep2 accurately identifies known and hundreds of novel microRNA genes in seven animal clades.</a> Nuc Acid Res. 40 (1), 37-52 (2012).</li>
<li>Chou, C. H., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Mirtarbase+2016%3A+Updates+to+the+experimentally+validated+miRNA-target+interactions+database%5BTitle%5D)+AND+%22Nuc+Acid+Res%22%5BJournal%5D)">Mirtarbase 2016: Updates to the experimentally validated miRNA-target interactions database.</a> Nuc Acid Res. 44 (D1), D239-D247 (2016).</li>
<li>Porichis, F., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((High-throughput+detection+of+miRNAs+and+gene-specific+mRNA+at+the+single-cell+level+by+flow+cytometry%5BTitle%5D)+AND+%22Nat+Commun%22%5BJournal%5D)">High-throughput detection of miRNAs and gene-specific mRNA at the single-cell level by flow cytometry.</a> Nat Commun. 5 (1), 5641(2014).</li>
<li>Eichert, A., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((The+crystal+structure+of+an+%27all+locked%27+nucleic+acid+duplex%5BTitle%5D)+AND+%22Nuc+Acid+Res%22%5BJournal%5D)">The crystal structure of an 'all locked' nucleic acid duplex.</a> Nuc Acid Res. 38 (19), 6729-6736 (2010).</li>
<li>Viratham Pulsawatdi, A., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((A+robust+multiplex+immunofluorescence+and+digital+pathology+workflow+for+the+characterisation+of+the+tumour+immune+microenvironment%5BTitle%5D)+AND+%22Mol+Oncol%22%5BJournal%5D)">A robust multiplex immunofluorescence and digital pathology workflow for the characterisation of the tumour immune microenvironment.</a> Mol Oncol. 14 (10), 2384-2402 (2020).</li>
<li>Janati-Idrissi, S., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Looking+for+a+needle+in+a+haystack%3A+De+novo+phenotypic+target+identification+reveals+hippo+pathway-mediated+mir-202+regulation+of+egg+production%5BTitle%5D)+AND+%22Nuc+Acid+Res%22%5BJournal%5D)">Looking for a needle in a haystack: De novo phenotypic target identification reveals hippo pathway-mediated mir-202 regulation of egg production.</a> Nuc Acid Res. 52 (2), 738-754 (2024).</li>
</ol>

The authors have nothing to disclose.

Though the importance of miRNAs is recognized and understood, observations of both normal development and disease states are currently hindered by the difficulty of studying miRNAs using standard methods. The scarcity of in situ methods led to the development of MARLIN (miRNA FISH assay). Given the homology and short length of miRNAs, it becomes a challenge to visualize their location and effect on post-transcriptomic regulation. This protocol development utilizes Locked Nucleic Acid Probes (LNA). LNAs are modif...

microRNAs 
Although microRNAs (miRNA) are incredibly small, ranging 19-25 nucleotides in length, these single-stranded RNA molecules are potent regulators in gene expression, modulating messenger RNAs (mRNAs) post-transcriptionally through sequence-specific interactions1. In essence, miRNAs act as negative regulators by binding to target mRNAs, either preventing their translation or promoting their degradation through mRNA cleavage, depending on the degree of complementarity, which ultimately leads to decreased protein output from the targeted gene. While miRNAs are basically non-coding RNA, approximately 40% of all miRNAs are still found within introns or exons of protein-coding genes2. The functional purpose of miRNAs encompasses several key biological processes such as cell proliferation, angiogenesis, apoptosis, etc. Notably, the dysregulation of miRNAs has been implicated in tumorigenesis, as aberrant expression of specific miRNAs and miRNA-mediated gene regulation has been associated with oncogenic transformation in multiple cancer types3.
Since their discovery, miRNAs have been extensively researched in various diseases due to their tissue-specific expression and regulatory functions, with their dysregulation linked to many diseases, including neurodegenerative disorders, autoimmune disorders, and various cancers4,5,6. The expression patterns of miRNAs can be correlated with cancer type, stage, and clinical variables, making miRNA profiling a valuable tool for cancer diagnosis and prognosis4,5,6,7. The discovery of new miRNAs has also been accelerated by advancements in high-throughput sequencing technologies, enhancing the understanding of miRNA involvement in diverse biological processes8. The significance of miRNAs was underscored by the 2024 Nobel Prize in Medicine awarded to Victor Ambros and Gary Ruvkun for their discovery of the function of miRNA in posttranscriptional regulation9.
As valuable biomarkers for disease diagnosis and prognosis, the therapeutic potential of miRNAs has been explored, leading to the development of miRNA-targeting drugs. The therapeutic potential of miRNAs in cancer treatment lies in their ability to coordinately regulate modules of genes, potentially restoring normal cellular functions10. Previously, miRNA-based anticancer therapies have been developed either as monotherapy or in combination with existing targeted therapies to enhance treatment responses and increase cure rates11. The dynamic spectrum of miRNAs has positioned them as essential resources for innovative cancer treatment strategies. In the context of therapeutic resistance, targeting miRNAs has shown promise in reducing recurrence and resistance to traditional cancer treatments, potentially improving patient survival by targeting cancer cells12. By exploring the roles of miRNAs in modulating the activities of various cell types in the tumor microenvironment (TME), unique and clinically relevant cancer treatments can potentially be discovered.
Available assays to detect miRNAs 
Currently, the most common method for miRNA measurement relies on extracted RNA for quantitative real-time PCR (q-RT-PCR) or Next Generation Sequencing (NGS), losing spatial context. There are companies that will provide TaqMan microRNA assays, which use target-specific stem-loop primers for cDNA synthesis, and SYBR Green dye-based chemistries with universal cDNA synthesis. These assays can offer high sensitivity and specificity and can be run on a range of q-RT-PCR instruments. Unfortunately, TaqMan assays cannot provide absolute quantification, which can lead to issues such as false positives and variability in results13. Also, despite their high sensitivity, the application of these assays in differing sample types can be limited by the need for extensive sample preparation and potential interference from other components in the sample.
Next-Generation Sequencing (NGS): miRNA-seq is increasingly popular for differential expression analysis across the entire miRNome of biofluids. A benefit of NGS technologies like miRNA-seq is that they allow for massive parallel analyses of the genome-wide expression of miRNAs, enabling the quantification of individual miRNAs, identification of sequence variations, and discovery of novel miRNAs14. A substantial drawback to sequencing-based methods, such as IlluminaTruSeq Small RNA Sample Preparation Kit, is the induction of quantitative biases, affecting the accuracy of differential expression analyses, due in large part to the homology and smaller read lengths of miRNAs14. Not only that, but the presence of isomiRs (variants that differ in sequence or length from the canonical miRNA sequence) and technical artifacts can complicate data interpretation, potentially leading to misdetections and confounding factors in biomarker assays14. Also, different tools for miRNA-seq data analysis, such as sRNAbench and miRDeep2, can yield varying results, affecting the consistency and reliability of novel miRNA discovery15,16. Even something like microarray technology can be insufficient in most cases. Though it can provide a powerful, high-throughput platform for detecting miRNA or gene expression levels, making it suitable for genome-wide studies, the technology is still limited by the number of previously identified miRNAs and cannot directly verify miRNA-target interactions, which limits their utility in functional studies17.
The most important factor that can be stressed here when comparing all these available options is the lack of spatial context. They do not provide any context in relation to the tissue morphology or spatiotemporal distribution within the cells. Visualizing the spatiotemporal behavior of miRNAs is necessary to unravel their function at the cellular and subcellular levels. Presently, miRNAscope in situ Hybridization (ISH) assays are accessible, usually utilizing chromogenic detection methods. While these assays do allow for the visualization of miRNA with single-cell resolution, the results are lacking in quality, making it difficult to differentiate between the miRNA expression and the background of the sample. Generally, many of these produce low-quality assays, which are unreliable and usually require manual quantification.
Therefore, we developed MicroRNA Amplification and Recognition through Locked-nucleic-acid in situ hybridizatioN (MARLIN) using multiplex immunofluorescence staining (by Opal protein staining) and locked nucleic acid (LNA) probes targeted to a miRNA, within formalin-fixed paraffin-embedded (FFPE) tissues. We accomplished this by implementing a Tyramide Signal Amplification (TSA) system that is activated by an Anti-Digoxigenin (DIG) Horseradish Peroxidase (HRP) Conjugate antibody. The HRP acts as a catalyst to the TSA, while the Anti-DIG attaches to the LNA probe. This assay is of particular use in understanding the essential nature of miRs in post-transcriptomic modification with proteins, and potentially other RNAs simultaneously. Furthermore, due to the lack of a commercially available assay that can quantify both miRNA and protein expression, MARLIN provides an effective way to understand the in situ relationships of miRs and proteins within FFPE samples.
The initial results from the quantification of miR-181c-3p using MARLIN demonstrated the feasibility of parallel analysis of miRNAs and proteins within the native spatial context of human ovarian FFPE tissue. Beyond this example, based on the components of MARLIN, it is theoretically possible to expand to up to four proteins utilizing commercial fluorescent multiplexing fluorophores like Alexa Fluor, or other small molecule dyes18.
In addition, since this methodology employs variations on standard histology methods, it should be compatible with other mammalian FFPE tissues, given appropriate probe and antibody selection. This methodology preserves spatial architecture and allows the quantification of cellular and subcellular miRNA and protein colocalization. This approach addresses a critical gap in spatial biology by mapping miRNAs-protein co-expression patterns and spatial distribution, which can be directly contextualized within native tissue architectures. Here we present MARLIN with a detailed graphical overview in Figure 1. While the protocol presented is optimized for miR-181c-3p, other miRs are possible to study, given an appropriate probe design. Critical parameters for this method include: the assessment of tissue quality and the optimization of probe concentrations. It is recommended to assess RNA integrity of the tissue block using a DV200 metric by utilizing two 10 &#181;m sections and extracting the RNA using a protocol that preserves all RNA fragment sizes. Samples with a DV200 score greater than 50 or better, and protocol concentrations, need to be systematically tested.

<table><tbody><tr><td>10x TRIS-buffered Saline (TBS) pH 7.6&amp;nbsp;</td><td>Thermo Fisher Scientific</td><td>&amp;nbsp;J62662&amp;nbsp;K7</td><td>For intermittent washes between steps</td></tr><tr><td>1x Opal Antibody Diluent/Block&amp;nbsp;</td><td>Akoya Biosciences</td><td>ARD1001EA</td><td>Protein blocking solution</td></tr><tr><td>1x Plus Automation Amplification Diluent</td><td>Akoya Biosciences&amp;nbsp;</td><td>FP1609</td><td>Used to dilute Opal fluorophores</td></tr><tr><td>20x Concentrate&amp;nbsp;Saline Sodium Citrate (SSC) Buffer</td><td>Sigma-Aldrich</td><td>S6639-1L</td><td>For miRNA washes after probe hybridization</td></tr><tr><td>4&#039;,6-diamidino-2-phenylindole (DAPI)&amp;nbsp;</td><td>Thermo Fisher Scientific/ Invitrogen</td><td>EN62248 / 62248</td><td>For nuclear staining</td></tr><tr><td>ACD HybEZ II Hybridization System</td><td>ACD Biotechne</td><td>321711</td><td>Oven used to regulate temperature during miRNAscope protocol</td></tr><tr><td>Anti-CD8 (D8A8Y), Rabbit mAb</td><td>Cell Signaling Technologies</td><td>85336S</td><td>Example of primary antibody used to optimize this protocol</td></tr><tr><td>Anti-Digoxigenin (Mouse) HRP Conjugate</td><td>Revvity Health Sciences Inc</td><td>NEF832001EA</td><td>Secondary reagent used for miRNA detection</td></tr><tr><td>Anti-EpCAM (E6V8Y), Rabbit mAb</td><td>Cell Signaling Technologies</td><td>93790</td><td>Example of primary antibody used to optimize this protocol</td></tr><tr><td>Blocking Reagent Powder</td><td>Akoya Biosciences&amp;nbsp;</td><td>FP1012</td><td>miRNA blocking solution</td></tr><tr><td>Ethyl Alcohol 100% (200 Proof)</td><td>Pharmco</td><td>111000200</td><td>For deparaffinization</td></tr><tr><td>EZ-AR1 Buffer</td><td>BioGeneX</td><td>HK521-XAK</td><td>Used for antigen retrieval of FFPE tissue sections at the protein step</td></tr><tr><td>EZ-AR1 Elegance Buffer</td><td>BioGeneX</td><td>HK546-XAK</td><td>Used for antigen retrieval of FFPE tissue sections at the miRNA probe step</td></tr><tr><td>EZ-Retriever IR System</td><td>BioGeneX</td><td>MW015-IR</td><td>Microwave used for antigen retrieval of FFPE tissue sections</td></tr><tr><td>Hydrogen Peroxide Solution 30%&amp;nbsp;</td><td>Sigma-Aldrich&amp;nbsp;</td><td>HX0640-5&amp;nbsp;</td><td>For Tissue preparation. Helps to block endogenous peroxidase activity and to yield highly colored products</td></tr><tr><td>miR-181c-3p miRNA Probe</td><td>Qiagen</td><td>339112</td><td>Example of miRNA probe used to optimize this protocol</td></tr><tr><td>miRCURY LNA miRNA ISH Buffer Set (FFPE)</td><td>Qiagen</td><td>339450&amp;nbsp;</td><td>Used to dilute miRNA probe</td></tr><tr><td>Opal 620</td><td>Akoya Biosciences&amp;nbsp;</td><td>FP1495001KT</td><td>Fluorophore to identify primary antibody</td></tr><tr><td>Opal 690&amp;nbsp;</td><td>Akoya Biosciences&amp;nbsp;</td><td>FP1497001KT</td><td>Fluorophore to identify primary antibody</td></tr><tr><td>Opal Anti-Ms + Rb HRP</td><td>Akoya Biosciences</td><td>ARH1001EA</td><td>Secondary antibody used as a detection agent</td></tr><tr><td>Pierce 16% Formaldehyde (w/v), Methanol-free</td><td>Thermo Fisher Scientific</td><td>28908</td><td>To make 3.7% PFA for tissue preparation</td></tr><tr><td>ProLong Diamond Antifade</td><td>Thermo Fisher Scientific</td><td>P36970</td><td>Mounting media</td></tr><tr><td>RNAscope Protease Plus</td><td>ACD Biotechne</td><td>322331</td><td>To permeabilize tissue sections&amp;nbsp;by partially digesting proteins &amp;amp; expose target miRNA molecules</td></tr><tr><td>RNAse-free water&amp;nbsp;</td><td>Corning&amp;nbsp;</td><td>46-000-CM&amp;nbsp;</td><td>To clean and prep all equipment, and to use as a dilutant when necessary&amp;nbsp;&amp;nbsp;</td></tr><tr><td>Tween 20</td><td>Sigma-Aldrich</td><td>P1379-25ML</td><td>To make TBS-T</td></tr><tr><td>Tyramide Signal Amplification Plus Cyanine 3</td><td>Akoya Biosciences&amp;nbsp;</td><td>NEL744001KT</td><td>Fluorophore to identify miRNA</td></tr><tr><td>U6 and Scramble miRNA Probes</td><td>Qiagen</td><td>339459</td><td>Optional control probes</td></tr><tr><td>Xylenes Histological Grade</td><td>Thermo Fisher Scientific</td><td>UN1307</td><td>For deparaffinization</td></tr></tbody></table>

microrna amplification and recognition through locked-nucleic-acid in situ hybridization as a novel detection and quantification method

MicroRNA Amplification and Recognition through Locked-nucleic-acid In situ Hybridization as a Novel Detection and Quantification Method

When using traditional probe-based in situ hybridization (ISH) imaging detection methods, microRNAs (miRNAs) are difficult to capture due to their size, which ranges from 19 to 25 nucleotides. However, as miRNAs are key epigenetic regulators that contribute to normal physiology and numerous pathological conditions, understanding the spatiotemporal behavior of miRNAs is important to unravel their function at the cellular and subcellular levels. This creates a clear need for adequate detection and visualization techniques. Therefore, we created MicroRNA Amplification and Recognition through Locked-nucleic-acid in situ hybridizatioN (MARLIN), which was developed and optimized utilizing multiplex immunofluorescence staining, and locked nucleic acid (LNA) probes targeted to a miRNA. This method can quantify miRNA with multiplexed protein expression, which allows the quantification of intracellular and extracellular miRNA within the tumor microenvironment (TME) with high sensitivity and reproducibility. The combined use of miRNA detection and protein capture assays can also provide a comprehensive understanding of cellular functions and regulatory mechanisms within that TME.

When testing this protocol, it is important to have two serial sections of the same representative sample for accuracy and comparison. In this case, a High-Grade Ovarian Cancer (HGSC) sample was used to compare the results. A control slide (Figure 2A-B) that would only go through the miRNA staining and a test slide that would undergo both protein and miRNA staining (Figure 2C-J) were used.
<p...

The protocol describes a tandem immunofluorescence hybridization assay with formalin-fixed paraffin-embedded tissue to detect and quantify microRNA and multiplexed proteins simultaneously.

When using traditional probe-based in situ hybridization (ISH) imaging detection methods, microRNAs (miRNAs) are difficult to capture due to their size, ...

The scope of our research was to develop and validate an assay that simultaneously detects and quantifies microRNAs and multiple proteins within FFPE tissue all the better to spatially observe the relationship between both within the TME. It actually overcomes common limitations of existing molecular sequencing and traditional-ish by providing a direct quantification, colocalization, and simultaneous spatial detection of microRNAs and proteins, all without destroying the tissue and preserving cell and subcellular localization. This technology potentially paves the way for both basic research into regulatory networks, disease mechanisms, and translational or clinical studies seeking better biomarkers and therapeutic targets.Begin by taking out formalin-fixed paraffin-embedded samples of human ovarian tumor, kept overnight at 60 degrees Celsius. Using RNAse-free water, clean all equipment and tools thoroughly. Next to perform deparaffinization, immerse the samples in xylene three times for five minutes each.Rehydrate the tissues with 10 rounds of sequential diluted ethanol series, each for three minutes. And then, wash the samples once in TBS for two minutes. Apply a 3%hydrogen peroxide solution to the samples for 10 minutes.Wash the samples twice for two minutes each with TBS. Then, apply a 3.7%paraformaldehyde solution for 10 minutes. After that, begin the first round of antigen retrieval using the easy retriever infrared system.Submerge the slides in fresh EZ-AR 1 buffer, and microwave at 95 degrees Celsius for 15 minutes. Then rinse the samples in TBS for two minutes, followed by two two minute washes in TBST. To begin, draw a barrier around each tissue section using a hydrophobic barrier pen.Add antibody blocking solution and incubate the slides for 30 minutes at room temperature in a humidity chamber. Now, apply the primary antibody diluted in the same blocking solution to fully cover the tissue section and incubate for one hour at room temperature in a humidity chamber. After washing the slides three times in TBST, add the anti-mouse and rabbit horseradish peroxidase solution to cover the tissue and incubate in the humidity chamber at room temperature for 10 minutes.Now, dilute the first fluoro-4 at a 1:100 ratio with amplification dilutant. Apply this mixture to the tissue and incubate for 10 minutes at room temperature in a humidity chamber, avoiding direct light exposure. After performing the second round of antigen retrieval and blocking as shown previously, dilute the second primary antibody with the same blocking solution.Apply the diluted antibody to cover the entire tissue section and incubate overnight for at least 16 hours at four degrees Celsius inside a humidity chamber. The next day, wash the slides three times for two minutes each in TBST and incubate with anti-mouse and rabbit horseradish peroxidase solution as shown earlier. Then, apply the diluted second fluoro-4 to the slides and incubate for 10 minutes at room temperature in the humidity chamber.For probe application, wash the slides three times for two minutes each in TBST. To begin the third and final antigen retrieval, submerge the slides in EZ-AR 1 Elegance buffer, and microwave at 107 degrees Celsius for 15 minutes. Cool the slides at room temperature for 20 minutes before washing them once for three minutes in TBS.Apply enough RNAscope Protease Plus to cover the tissue area and incubate at 40 degrees Celsius for 30 minutes using an oven. Then, heat the microRNA locked nucleic acid probe to 90 degrees Celsius for four minutes to denature it. Immediately dilute the denatured probe with microRNA in situ hybridization buffer.After vortexing and spinning the prepared probe, add it to cover the entire tissue area and incubate for one hour at 60 degrees Celsius in the oven. Wash the slides once for five minutes in 5x SSC Buffer. Perform five stringent washes at 60 degrees Celsius using SSC Buffer for five minutes each.Then, wash the slides once for five minutes in 0.2 times SSC at room temperature. To prepare the blocking buffer, combine TBS and 0.5%blocking reagent powder. Apply the blocking buffer and incubate for 30 minutes at room temperature in a humidified chamber.Next, apply anti-digoxin and mouse horseradish peroxidase conjugate, and incubate for 30 minutes at room temperature in a humidified chamber. After three TBST washes, apply 1:50 dilution of the tyramide signal amplification plus cyanine 3 to the slides for 10 minutes at room temperature in a humidity chamber. Wash the slides three more times for five minutes each in TBST.Apply enough DAPI working solution diluted 1:1000 in TBS to fully cover the tissue section. Incubate the slides for five minutes at room temperature in a humidified chamber with ambient humidity. Wash the slides three times for five minutes each in TBST.Apply cover slips using mounting media and let the slides dry for 10 minutes at room temperature. Store the dried slides at four degrees Celsius in the dark for 24 to 72 hours before imaging or up to three months for longer term storage. The miRNA expression of miR-181c-3p was consistently detected in both control and antibody stained slides, with visibly stronger signals concentrated in the tumor cell regions.Application of the anti-EpCAM antibody with a 620 nanometer emission fluorophore stained the tumor cells in the HGSC sample. Application of the anti-CD8 antibody with a 620 nanometer emission fluorophores distinctly marked CD8 positive T-cell. Combined protein and miRNA detection enabled spatial localization of miR-181c-3p relative to EpCAM positive tumor cells and CD8 positive immune cells.The positive control probe targeting U6 small nuclear RNA produced strong fluorescent signals across all tissue types, confirming probe effectiveness and tissue integrity. The negative control probe which used a scrambled miRNA sequence showed no detectable signal in any tissue type, indicating no non-specific binding. The target probe for miR-181c-3p showed strong expression in the high-grade serous carcinoma tissue with no signal in normal ovarian tissue or normal fallopian tube tissue, demonstrating the specificity and accuracy of the probe and assay.

microrna-amplification-recognition-through-locked-nucleic-acid-situ

Research

JoVE Journal

Cancer Research

Here we describe an optimized multiplex reverse transcriptase quantitative PCR (qRT-PCR) protocol in combination with a microfluidic platform as a cost and time effective high-throughput screening tool for microRNA (miRNA) expression levels, especially when working with limited amounts of sample.

High Throughput MicroRNA Profiling: Optimized Multiplex qRT-PCR at Nanoliter Scale on the Fluidigm Dynamic ArrayTM IFCs

A novel high-throughput method is described that enables the detection and relative quantitation of small RNA and mRNA expression from single bacterial cells using locked nucleic acid probes and flow cytometry-fluorescence in situ hybridization.

Locked Nucleic Acid Flow Cytometry-fluorescence in situ Hybridization (LNA flow-FISH): a Method for Bacterial Small RNA Detection

This video describes a sequential hybridization strategy that involves hybridizing mRNA probes to specific target mRNA. Following probe hybridization, signal amplification is performed to enhance resolution via reduction of signal-to-noise ratio during RNA-CISH of histological samples.

Probe Hybridization and Signal Amplification in RNA In Situ Hybridization: A Technique for Detecting Specific RNA Sequences in Tissue Sections

The aim of this publication is to visualize and discuss the operative steps of an Enhanced Northern Blot protocol on RNA extracted from Drosophila melanogaster embryos, cells, and tissues. This protocol is particularly useful for the efficient detection of small RNA species.

Enhanced Northern Blot Detection of Small RNA Species in Drosophila Melanogaster

MicroRNAs (miRNAs) are a widely conserved class of regulatory molecules. Here we describe a miRNA cloning method that relies upon two potent ligation steps followed by high-throughput sequencing. Our method permits accurate genome-wide quantitation of miRNAs.

Highly Efficient Ligation of Small RNA Molecules for MicroRNA Quantitation by High-Throughput Sequencing

Circulating microRNAs have recently emerged as promising and novel biomarkers for various cancers and other diseases. The goal of this article is to discuss three different probe-based real-time PCR platforms and methods that are available to quantify and determine the abundance of circulating microRNAs.

Probe-based Real-time PCR Approaches for Quantitative Measurement of microRNAs

Here we present a protocol to detect miRNA expression in breast cancer patient samples using miRNA in situ hybridization.

Clinicopathological Analysis of miRNA Expression in Breast Cancer Tissues by Using miRNA In Situ Hybridization

This report describes a fast and reliable method for validating mRNA targets of cellular miRNAs. The method uses synthetic biotinylated Locked Nucleic Acid (LNA)-based miRNA mimics to capture target mRNA. Subsequently, streptavidin-coated magnetic beads are employed to pulldown the target mRNA for quantification by qPCR polymerase chain reaction.

Biotin-based Pulldown Assay to Validate mRNA Targets of Cellular miRNAs

To reproducibly count the numbers of mRNAs in individual oocytes, single molecule RNA fluorescence in situ hybridization (RNA-FISH) was optimized for non-adherent cells. Oocytes were collected, hybridized with the transcript specific probes, and quantified using an image quantification software.

Use of Single Molecule Fluorescent In Situ Hybridization (SM-FISH) to Quantify and Localize mRNAs in Murine Oocytes

This method demonstrates use of the northern hybridization technique to detect miRNAs from total RNA extract.

RNA Blot Analysis for the Detection and Quantification of Plant MicroRNAs

The DNAzyme-based nanomachines can be used for highly selective and sensitive detection of nucleic acids. This article describes a detailed protocol for the design of DNAzyme-based nanomachines with a 10-23 core using free software and their application in the detection of an Epstein-Barr virus fragment as an example.

DNAzyme 10-23 - Based Nanomachines for Nucleic Acid Recognition

Learn a tandem immunofluorescence hybridization assay to detect and quantify microRNAs and proteins in FFPE tissue. This method preserves tissue integrity while enabling spatial analysis of tumor microenvironments.

MicroRNA Amplification and Recognition through Locked-nucleic-acid In situ Hybridization as a Novel Detection and Quantification Method (Video) | JoVE Journal

MicroRNA Amplification and Recognition through Locked-nucleic-acid In situ Hybridization as a Novel Detection and Quantification Method

Explore More Videos